Literature DB >> 1391235

Interleukin-6 production by human melanoma cell lines.

J D Lee1, T M Sievers, M Skotzko, C F Chandler, D L Morton, W H McBride, J S Economou.   

Abstract

We examined the expression of interleukin-6 (IL-6) by 12 established human melanoma cell lines. Two constitutively produced low levels of IL-6 protein, as measured by enzyme-linked immunosorbent assay. Cells from these two lines, as well as those from two non-IL-6-producing cell lines, contained IL-6-specific mRNA as demonstrated by Northern hybridization. Treatment of the two IL-6-producing melanoma cell lines with interleukin-1 beta, tumor necrosis factor-alpha, or phorbol myristate acetate caused a marked increase in IL-6 production. These induction signals failed to stimulate IL-6 production in the nonproducing cells, even those that expressed IL-6 mRNA. IL-6 did not appear to act as an autocrine growth factor since the addition of exogenous human recombinant IL-6 or polyclonal anti-IL-6 antibody did not alter cellular proliferation. The production of this multifunctional cytokine by tumors may play a role in tumor-host interactions and this should be recognized in the design of biologic therapy trials.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1391235

Source DB:  PubMed          Journal:  Lymphokine Cytokine Res        ISSN: 1056-5477


  7 in total

1.  A possible growth factor role of IL-6 in neuroectodermal tumours.

Authors:  E Candi; R A Knight; A Spinedi; P Guerrieri; G Melino
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

2.  Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma.

Authors:  Maurizio Soresi; Lydia Giannitrapani; Fabio D'Antona; Ada-Maria Florena; Emanuele La Spada; Angela Terranova; Melchiorre Cervello; Natale D'Alessandro; Giuseppe Montalto
Journal:  World J Gastroenterol       Date:  2006-04-28       Impact factor: 5.742

3.  Interleukin-6 gene ablation in a transgenic mouse model of malignant skin melanoma.

Authors:  Verena von Felbert; Francisco Córdoba; Jakob Weissenberger; Claudio Vallan; Masashi Kato; Izumi Nakashima; Lasse Roger Braathen; Joachim Weis
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

4.  Loss of tumoral expression of soluble IL-6 receptor is associated with disease progression in colorectal cancer.

Authors:  Y Okugawa; C Miki; Y Toiyama; H Yasuda; T Yokoe; S Saigusa; J Hiro; K Tanaka; Y Inoue; M Kusunoki
Journal:  Br J Cancer       Date:  2010-09-07       Impact factor: 7.640

5.  Expression and up-regulation of interleukin-6 in oesophageal carcinoma cells by n-sodium butyrate.

Authors:  L S Wang; K C Chow; C W Wu
Journal:  Br J Cancer       Date:  1999-07       Impact factor: 7.640

6.  Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients.

Authors:  E Tartour; T Dorval; V Mosseri; L Deneux; C Mathiot; H Brailly; F Montero; I Joyeux; P Pouillart; W H Fridman
Journal:  Br J Cancer       Date:  1994-05       Impact factor: 7.640

7.  Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase.

Authors:  M Deichmann; B Kahle; K Moser; J Wacker; K Wüst
Journal:  Br J Cancer       Date:  2004-08-16       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.